Inhibitor of nuclear factor kappa-B kinase subunit alpha and Inhibitor of nuclear factor kappa-B kinase subunit beta (IKKα (for alpha subunit), IKKβ (for beta subunit))

The inhibitor of nuclear factor kappa-B kinase complex consists of two catalytic subunits—IKKα and IKKβ—and a regulatory subunit (NEMO/IKKγ). IKKα and IKKβ are serine/threonine kinases that orchestrate the activation of the transcription factor NF-κB by phosphorylating the inhibitory protein IκBα, marking it for degradation and allowing NF-κB to enter the nucleus and regulate genes involved in inflammation, cell survival, and immunity[1][2][4][7]. IKKβ is the primary mediator in the canonical NF-κB pathway, while IKKα is critical for non-canonical NF-κB signaling and also contributes redundantly in certain contexts. Both subunits have important but distinct roles in development, immunity, and disease, and have been implicated as therapeutic targets in various cancers, chronic inflammatory conditions, autoimmune diseases, and metabolic and neurodegenerative disorders. Small molecule inhibitors targeting IKKβ and IKKα are under investigation, but potential side effects stemming from interference with essential immune and survival pathways remain a challenge to clinical application[1][2][4][5][7].

Other names

IKK-alpha (IKKα)IKK-beta (IKKβ)IkappaB kinase alphaIkappaB kinase betaCHUK (for IKKα)IKBKB (for IKKβ)IKK1 (for IKKα)IKK2 (for IKKβ)Nuclear factor NF-kappa-B inhibitor kinase alpha/beta

Inhibition of IKKα/β blocks phosphorylation and degradation of IκB, preventing activation of NF-κB and downstream transcription of pro-inflammatory and survival genes[2][3]. - Some drugs act as ATP-competitive inhibitors of the kinase domain.